MPG.eBooks - Search Results - "Multiple Sclerosis"

Cover Image

1

Pharmacoeconomic review report: Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (R...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

2

Pharmacoeconomic review report: Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (R...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

3

Pharmacoeconomic review report: Daclizumab (Zinbryta)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

4

Medicines used for multiple sclerosis : a health technology assessment

by Couto, Elisabeth
Published 2016

Norwegian Institute for Public Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

5

Pharmacoeconomic review report: Daclizumab (Zinbryta)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

6

Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2017

CADTH

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

7

CADTH Canadian Drug Expert Committee recommendation: Cladribine (Mavenclad -- EMD Serono) : indication: relapsing-remitting multiple sclerosis

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

8

CADTH Canadian Drug Expert Committee recommendation: Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

9

Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Chronic Progressive / drug therapy...”

Cover Image

10

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

11

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

12

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) : indication : management of adult patients with early primary progressive mult...

Published 2018

CADTH

Subjects: “...Multiple Sclerosis / drug therapy...”

Cover Image

13

Neurorehabilitation: Looking Back and Moving Forward

by Nasios, Grigorios
Published 2023

MDPI - Multidisciplinary Digital Publishing Institute

Subjects: “...multiple sclerosis...”

Cover Image

14

The Impact of the COVID-19 Emergency on the Quality of Life of the General Population

by Roccella, Michele
Published 2022

MDPI - Multidisciplinary Digital Publishing Institute

Subjects: “...multiple sclerosis...”